Research & Development
Eli Lilly includes more firms in its lawsuits against counterfeit Mounjaro
20 June 2024 -

US-based drug maker Eli Lilly (NYSE:LLY) said on Thursday that is suing six more entities that are accused of selling counterfeit Mounjaro, Reuters reported on Thursday.

Medical spas and wellness centres are among the businesses facing legal action for allegedly selling products claimed to contain tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro.

Eli Lilly is the only company that has been approved by US Food and Drug Administration to sell the drug.

Lilly has also warned consumers against the use of counterfeit, fake, compounded, and any other unsafe or untested versions of what is claimed to be tirzepatide.